Ultragenyx Announces Positive Multi-Year Durability Data from Ongoing Phase 1/2 Gene Therapy Studies and Data on HeLa 3.0 Manufacturing Platform at American Society of Gene & Cell Therapy 2021 Annu
May 14, 2021
Posted by Ultragenyx
May 14, 2021
Posted by Ultragenyx